Sodium valproate, an anticonvulsant drug, stimulates human cytomegalovirus replication

References

1. Alford C. A., Britt W. J. 1990; Cytomegalovirus. In Virology 2nd edn., pp 1981–2010 Edited by Fields B. N., Knipe D. M. New York: Raven Press;
   [Google Scholar]
2. Ash R. J. 1986; Butyrate-induced reversal of herpes simplex virus restriction in neuroblastoma cells. Virology 155:584–592
   [Google Scholar]
3. Attaguile G., Caruso A., Cutuli V. M. C., Di Giacomo C., Russo A., De Bernardis E., Amico-Roxas M. 1992; Influence of sodium valproate and carbamazepine on GSH levels in rat cerebral cortex. Drugs under Experimental and Clinical Research 18:465–467
   [Google Scholar]
4. Bohan C. A., Robinson R. A., Luciw P. A., Srinivasan A. 1989; Mutational analysis of sodium butyrate inducible elements in the human immunodeficiency virus type 1 long terminal repeat. Virology 172:573–583
   [Google Scholar]
5. Bradford M. M. 1976; A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Analytical Biochemistry 72:248–254
   [Google Scholar]
6. Braun R. W., Reiser H. C. 1986; Replication of human cytomegalovirus in human peripheral blood T-cells. Journal of Virology 60:29–36
   [Google Scholar]
7. Buhl R., Holroyd K. J., Mastrangeli A., Cantin A. M., Jaffe H. A., Wells F. B., Saltini C., Crystal R. G. 1989; Systemic glutathione deficiency in symptom-free HIV seropositive individuals. Lancet ii:1294–1297
   [Google Scholar]
8. Chapman A., Keane P. E., Meldrum B. S., Simiand J., Vernieres J. C. 1982; Mechanism of anticonvulsant action of valproate. Progress in Neurobiology 19:315–359
   [Google Scholar]
9. Cotariu D., Evans S., Zaidman J. L., Marcus O. 1990; Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid. Biochemical Pharmacology 40:589–593
   [Google Scholar]
10. Cotariu D., Evans S., Lahat E., Theitler J., Bistritzer T., Zaidman J. L. 1992; Inhibition of human red blood cell glutathione reductase by valproic acid. Biochemical Pharmacology 43:425–29
    [Google Scholar]
11. Dreifuss F. E., Santilli N., Langer D. H., Sweeney K. P., Moline K. A., Menander K. B. 1987; Valproic acid hepatic fatalities: a retrospective review. Neurology 37:379–385
    [Google Scholar]
12. Drew W. L. 1988; Cytomegalovirus infection in patients with AIDS. Journal of Infectious Diseases 158:449–456
    [Google Scholar]
13. Fulbert J.-C., Cals M.-J. 1992; Les radicaux fibres en biologie clinique: origine, role pathogene et moyens de defense. Pathologie Biologie 40:66–77
    [Google Scholar]
14. Ghazal P., Lubon H., Fleckenstein B., Hennighausen L. 1987; Binding of transcription factors and creation of a large nucleoprotein complex on the human cytomegalovirus enhancer. Proceedings of the National Academy of Sciences, USA 84:3658–3662
    [Google Scholar]
15. Ghazal P., Lubon H., Hennighausen L. 1988; Multiple sequence-specific transcription factors modulate cytomegalovirus enhancer activity in vitro. Molecular and Cellular Biology 8:1809–1811
    [Google Scholar]
16. Graham F. L., van der Eb A. J. 1973; A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456
    [Google Scholar]
17. Israël N., Gougerot-Pocidalo M.-A., Aillet F., Virelizier J. L. 1992; Redox status of cells influences constitutive or induced NF-κB translocation and HIV long terminal repeat activity in human T and monocytic cell fines. Journal of Immunology 149:3386–3393
    [Google Scholar]
18. Kalebic T., Kinter A., Poli G., Anderson M. E., Meister A., Fauci A. S. 1991; Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and V-acetylcysteine. Proceedings of the National Academy of Sciences, USA 88:986–990
    [Google Scholar]
19. Laughlin M. A., Zeichner S., Kolson D., Alwine J. C., Ses-hamma T., Pomerantz R. J., Gonzales-Scarano F. 1993; Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology 196:496–505
    [Google Scholar]
20. Luka J., Kallin B., Klein G. 1979; Induction of the Epstein–Barr virus (EBV) cycle in latently infected cell by n-butyrate. Virology 94:228–231
    [Google Scholar]
21. Mach M., Stamminger T., Jahn G. 1989; Human cytomegalovirus: recent aspects from molecular biology. Journal of General Virology 18:3117–3146
    [Google Scholar]
22. Meister A. 1991; Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacology and Therapeutics 51:155–194
    [Google Scholar]
23. Mossman T. 1983; Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65:55–63
    [Google Scholar]
24. Nabel G., Baltimore D. 1987; An inducible transcription factor activates expression of human immunodeficiency virus in T-cells. Nature 326:711–713
    [Google Scholar]
25. Niller H. H., Hennighausen L. 1990; Phytohemagglutinin-mduced activity of cyclic-AMP (cAMP). Response element from cytomegalovirus is reduced by cyclosporine and synergistically enhanced by cAMP. Journal of Virology 64:2388–2391
    [Google Scholar]
26. Nordhoff A., Schirmer R. H., Mayatepek E., Becker K. 1994; No evidence for inhibition of human glutathione reductase by valproic acid. Biochemical Pharmacology 46:199–204
    [Google Scholar]
27. Prasad K. N., Sinha P. K. 1976; Effects of sodium butyrate on mammalian cells in culture: a review. In Vitro 12:125–132
    [Google Scholar]
28. Radsak K., Fuhrmann R., Franke R. P., Schneider D., Kollert A., Brucher K. H., Drenckhahn D. 1989; Induction by sodium butyrate of cytomegalovirus replication in human endothelial cells. Archives of Virology 107:151–158
    [Google Scholar]
29. Reed L. J., Muench H. 1938; A simple method of estimating fifty percent endpoints. American Journal of Hygiene 27:493
    [Google Scholar]
30. Rice G. P. A., Schrier R. D., Oldstone M. B. A. 1984; Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to IE gene products. Proceedings of the National Academy of Sciences, USA 81:6134–6138
    [Google Scholar]
31. Roederer M., Staal F. J. T., Raju P. A., Ela S. W., Herzenberg L. A., Herzenberg L. A. 1990; Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyi-L-cysteine. Proceedings of the National Academy of Sciences, USA 87:4884–4888
    [Google Scholar]
32. Saemundsen A. K., Kallin B., Klein G. 1980; Effect of n- butyrate on cellular and viral DNA synthesis in cells latently infected with Epstein–Barr virus. Virology 107:557–561
    [Google Scholar]
33. Sambucetti L. C., Cherrington J. M., Wilkinson G. W. G., Mocarski E. S. 1989; NF-κ B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T-cell stimulation. EM BO Journal 8:4251–1258
    [Google Scholar]
34. Schreck R., Rieber P., Baeuerle P. A. 1991; Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κ B transcription factor and HIV-1. EMBO Journal 10:2247–2258
    [Google Scholar]
35. Schrier R. D., Nelson J. A., Oldstone M. B. A. 1985; Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science 230:1048–1051
    [Google Scholar]
36. Simon G., Moog C., Obert G. 1994; Valproic acid reduces the intracellular level of glutathione and stimulates human immunodeficiency virus. Chemico-Biological Interactions 91:111–121
    [Google Scholar]
37. Staal F. J. T., Roederer M., Herzenberg L. A., Herzenberg L. A. 1990; Intracellular thiols regulate activation of nuclear factor kB and transcription of human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 87:9943–9947
    [Google Scholar]
38. Stinski M. F. 1990; Cytomegalovirus and its replication. In Virology 2nd edn., pp 1959–1980 Edited by Fields B. N., Knipe D. M. New York: Raven Press;
    [Google Scholar]
39. Tanaka J., Sadanari H., Sato H., Fukuda S. 1991; Sodium butyrate-inducible replication of human cytomegalovirus in a human epithelial cell line. Virology 185:271–280
    [Google Scholar]
40. Toledano M. B., Leonard W. J. 1991; Modulation of transcription factor NF-κ B binding activity by oxidation-reduction in vitro. Proceedings of the National Academv of Sciences, USA 88:4328–1332
    [Google Scholar]
41. Vamecq J., Vallee L., Fontaine M., Nuyts J.-P., Lambert D., Poupaert J. 1993; Preliminary studies about novel strategies to reverse chemoresistance to adriamycin regarding glutathione metabolism, peroxisomal and extraperoxisomal hydroperoxide and valproic acid metabolic pathways. Biology of the Cell 77:17–26
    [Google Scholar]
42. Van den Branden C., Roels F. 1985; Peroxisomal β-oxidation and sodium valproate. Biochemical Pharmacology 34:2147–2149
    [Google Scholar]